FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of
FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or
unresectable gastroesophageal and gastric adenocarcinoma. Our primary objective is to
determine the time to progression in patients treated with FOLFOX in combination with
bevacizumab.